LCN2 and breast carcinoma: Moreover, in both cholangiocarcinoma (CCA) and breast cancer cells, the siRNA technology to silence Lcn-2 was tested, whereby in the former study, the knock-down of Lcn-2 in the cholangiocarcinoma cell line RMCCA-1 reduced its metastatic properties in vitro.